RBC Sees Execution Risks in Perspective Therapeutics' Drug Development
RBC said Perspective Therapeutics continues to face execution risks in developing bamzireotide navoxetan.
Related stories
US Air Travel Disruptions Continue for Third Day, 5,200 Flights Affected
More than 5,200 flights had been affected by Sunday as airlines worked to restore schedules. Transportation Secretary Sean Duffy predicted a return to normal by Monday.
M impact | EQUITY | Nov 15, 2026, 04:45 PM UTC
Duffy Says US Air Travel Disruption Will End by Tomorrow
Transportation Secretary Sean Duffy told NBC the disruption would be over by the end of today or tomorrow.
L impact | EQUITY | Nov 15, 2026, 02:24 PM UTC
US Air Travel Disruption Expected to End by Tomorrow, Duffy Says
Transportation Secretary Sean Duffy told NBC the US air travel disruption will be over by the end of today or tomorrow.
L impact | EQUITY | Nov 15, 2026, 02:05 PM UTC
Transportation Secretary Duffy Says US Air Travel Disruption Will End Soon
Duffy told NBC the disruption would be over by “end of today, end of tomorrow.”
L impact | EQUITY | Nov 15, 2026, 02:05 PM UTC
ESS Tech Files for Chapter 7 Bankruptcy and Ceases Operations
ESS Tech filed for Chapter 7 bankruptcy and terminated all employees and officers without cause. The iron flow battery company said it took the action after considering available s
M impact | EQUITY | Nov 15, 2026, 02:04 PM UTC
BMW Recalls 720,796 US Vehicles Over Potential Fire Risk
The recall affects several BMW models manufactured between 2012 and 2018. Safety regulators are asking owners to park affected vehicles outside and away from buildings until the pr
M impact | EQUITY | Nov 15, 2026, 02:03 PM UTC